Another Latuda setback as Takeda exits alliance
This article was originally published in Scrip
Executive Summary
Takeda Pharmaceutical has ended an alliance with fellow Japanese firm Sumitomo Dainippon Pharma for Latuda (lurasidone), dealing the second major blow to the atypical antipsychotic in recent weeks.